Long‐acting cabotegravir and rilpivirine in people with HIV and obesity: Real‐world outcomes from the RELATIVITY cohort

Abstract Introduction Long‐acting injectable cabotegravir and rilpivirine (LAI CAB + RPV) is a well‐established regimen for people with HIV (PWH) that offers high efficacy and tolerability. However, data are limited for obese individuals with a body mass index (BMI) ≥ 30 kg/m 2 , which may represent a potential risk factor for virologic failure (VF). Methods We conducted a multicentre, ambispective study (RELATIVITY cohort, Spain) of virologically suppressed PWH with BMI ≥ 30 kg/m 2 who switched to LAI CAB + RPV. This study characterized this population and evaluated the factors associated with virologic outcomes, tolerability and adherence using Kaplan–Meier analysis. Results Among the 3,203 individuals recruited in the RELATIVITY cohort, 57 were excluded due to detectable HIV RNA at the time of switching to LAI CAB+RPV, and 3,146 were finally included, all of whom had HIV RNA levels